"Cholesterol, LDL" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol.
| Descriptor ID |
D008078
|
| MeSH Number(s) |
D04.210.500.247.808.197.244 D10.532.515.500 D10.570.938.208.275 D12.776.521.550.500
|
| Concept/Terms |
Cholesterol, LDL- Cholesterol, LDL
- Low Density Lipoprotein Cholesterol
- beta-Lipoprotein Cholesterol
- Cholesterol, beta-Lipoprotein
- beta Lipoprotein Cholesterol
- LDL Cholesterol
|
Below are MeSH descriptors whose meaning is more general than "Cholesterol, LDL".
Below are MeSH descriptors whose meaning is more specific than "Cholesterol, LDL".
This graph shows the total number of publications written about "Cholesterol, LDL" by people in this website by year, and whether "Cholesterol, LDL" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 1 | 3 | 4 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 6 | 7 |
| 2000 | 1 | 5 | 6 |
| 2001 | 1 | 6 | 7 |
| 2002 | 2 | 6 | 8 |
| 2003 | 2 | 11 | 13 |
| 2004 | 1 | 7 | 8 |
| 2005 | 4 | 9 | 13 |
| 2006 | 6 | 7 | 13 |
| 2007 | 4 | 6 | 10 |
| 2008 | 7 | 4 | 11 |
| 2009 | 5 | 6 | 11 |
| 2010 | 2 | 10 | 12 |
| 2011 | 10 | 16 | 26 |
| 2012 | 3 | 15 | 18 |
| 2013 | 11 | 15 | 26 |
| 2014 | 12 | 14 | 26 |
| 2015 | 8 | 10 | 18 |
| 2016 | 10 | 14 | 24 |
| 2017 | 5 | 11 | 16 |
| 2018 | 8 | 9 | 17 |
| 2019 | 13 | 14 | 27 |
| 2020 | 6 | 10 | 16 |
| 2021 | 8 | 10 | 18 |
| 2022 | 1 | 23 | 24 |
| 2023 | 0 | 20 | 20 |
| 2024 | 4 | 13 | 17 |
| 2025 | 5 | 10 | 15 |
| 2026 | 1 | 6 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cholesterol, LDL" by people in Profiles.
-
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2026 American College of Cardiology Conference. Curr Atheroscler Rep. 2026 May 16; 28(1).
-
Statin Use and Recurrent Atherosclerotic Cardiovascular Disease Events in Patients With Coronary Artery Intervention: A Retrospective Analysis From a Large Health Care Network. J Am Heart Assoc. 2026 Mar 17; 15(6):e041416.
-
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial. Nat Med. 2026 Mar; 32(3):1052-1060.
-
The evolving therapeutic landscape of PCSK9 inhibition. Atherosclerosis. 2026 Mar; 414:120670.
-
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. N Engl J Med. 2026 Feb 05; 394(6):529-539.
-
The impact of genetic testing on physician practice in specialized cardiovascular clinics. J Clin Lipidol. 2026 Mar; 20(3):677-681.
-
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. JAMA. 2026 01 13; 335(2):129-139.
-
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 2026 Feb; 14(2):123-136.
-
Genome-wide gene-sleep interaction study identifies novel lipid loci in 732,564 participants. Atherosclerosis. 2026 Jan; 412:120603.
-
The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications. Eur Heart J. 2025 Nov 21; 46(44):4737-4750.